5α还原酶抑制剂对前列腺增生组织内雌激素受体、雄激素受体表达的影响

Effects of 5α reductor inhibitors on the expression of estrogen receptor and androgen receptor in the tissues of prostatic hyperplasia

目的研究5α还原酶抑制剂(5α-RI)对良性前列腺增生(BPH)患者前列腺组织内雄激素受体(AR)、雌激素受体α(ERα)、雌激素受体β(ERβ)表达的影响。方法选择100例BPH患者随机分为4组,每组25例,对照组口服维生素C 0.1 g,1次/d,非那雄胺组口服非那雄胺5 mg,1次/d,度他雄胺组口服度他雄胺治疗0.5 mg,1次/d,依立雄胺组口服依立雄胺5 mg,2次/d,治疗8周后行经尿道前列腺电切术,采用免疫组化方法观察术后前列腺组织内AR、ERα、ERβ的表达情况。结果采用IHS法对免疫组化结果进行半定量分析,其中AR表达方面,对照组(10.36±1.63)、非那雄胺组(9.08±1.71)、度他雄胺组(9.12±2.42)、依立雄胺组(7.92±2.36)之间差异有统计学意义(P<0.05),且依立雄胺组下降更为显著。ERα表达各组间变化不明显。与对照组ERβ表达(5.24±1.20)比较,度他雄胺组(6.52±1.57)、依立雄胺组(6.76±1.55)表达显著增强,非那雄胺组(5.60±1.04)表达有所增强,但差异无统计学意义(P>0.05)。结论 5α-RI可抑制BPH患者前列腺组织内的AR表达,增强ERβ表达,对ERα表达影响不大,不同5α-RI对AR、ERα、ERβ表达的影响程度有差异。

Objective To explore the effects of 5α reductor inhibitors （5α-RI） on the expression of androgen receptor, estrogen receptor α（ERα） and estrogen receptor β（ERβ） in the prostatic tissues in the patients with benign prostatic hyperplasia （BPH）. Methods A total of 100 patients with BPH were randomly assigned to four groups, with 25 patients in each group. The control group was orally given vitamin C of 0.1 g, once a day. Finasteride group was orally given finas-teride of 5 mg, once a day. Dutasteride group was orally given dutasteride of 0.5 mg, once a day. Epristeride group was orally given epristeride of 5 mg, twice a day. Prostate electrocision was performed via urethra 8 weeks after the treat- ment, and the expression of AR, ERα, and ERβ in the prostatic tissues was observed after the surgery via immunohis- tochemistry. Results IHS method was applied to conduct semi-quantitative analysis on the results of immunohisto- chemistry. There were significant differences of AR expression between the control group（10.36±1.63）, finasteride group （9.08±1.71）, dutasteride group （9.12±2.42） and epristeride group （7.92±2.36）, and the reduction in epristeride group was more significant（P〈0.05）. There were not significant changes of ERα expression between each group. The expression of ER[3 in dutasteride group （6.52±1.57） and epristeride group （6.76±1.55） was significantly enhanced compared with that in the control group（5.24±l.20）, and the expression in finasteride group（5.60±1.04） was enhanced, but there were no statistically significant differences（P〉0.05）. Conclusion 5α-RI is able to inhibit AR expression and enhance ERβ expression in the prostatic tissues in the patients with BPH. It does not have great effects on the expression of ERα. Different 5α-RIs have different effects on the expression of AR, ERα and ERβ.